Chargement en cours...

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study

PURPOSE: Combination treatment with immune checkpoint inhibitors has shown enhanced antitumor activity compared with monotherapy in tumor types such as melanoma. The open-label, parallel-cohort, dose-escalation, phase I CheckMate 016 study evaluated the efficacy and safety of nivolumab plus ipilimum...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Clin Oncol
Auteurs principaux: Hammers, Hans J., Plimack, Elizabeth R., Infante, Jeffrey R., Rini, Brian I., McDermott, David F., Lewis, Lionel D., Voss, Martin H., Sharma, Padmanee, Pal, Sumanta K., Razak, Albiruni R. Abdul, Kollmannsberger, Christian, Heng, Daniel Y.C., Spratlin, Jennifer, McHenry, M. Brent, Amin, Asim
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2017
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7587408/
https://ncbi.nlm.nih.gov/pubmed/28678668
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.72.1985
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!